45 research outputs found

    PANC Study (Pancreatitis: A National Cohort Study): national cohort study examining the first 30 days from presentation of acute pancreatitis in the UK

    Get PDF
    Abstract Background Acute pancreatitis is a common, yet complex, emergency surgical presentation. Multiple guidelines exist and management can vary significantly. The aim of this first UK, multicentre, prospective cohort study was to assess the variation in management of acute pancreatitis to guide resource planning and optimize treatment. Methods All patients aged greater than or equal to 18 years presenting with acute pancreatitis, as per the Atlanta criteria, from March to April 2021 were eligible for inclusion and followed up for 30 days. Anonymized data were uploaded to a secure electronic database in line with local governance approvals. Results A total of 113 hospitals contributed data on 2580 patients, with an equal sex distribution and a mean age of 57 years. The aetiology was gallstones in 50.6 per cent, with idiopathic the next most common (22.4 per cent). In addition to the 7.6 per cent with a diagnosis of chronic pancreatitis, 20.1 per cent of patients had a previous episode of acute pancreatitis. One in 20 patients were classed as having severe pancreatitis, as per the Atlanta criteria. The overall mortality rate was 2.3 per cent at 30 days, but rose to one in three in the severe group. Predictors of death included male sex, increased age, and frailty; previous acute pancreatitis and gallstones as aetiologies were protective. Smoking status and body mass index did not affect death. Conclusion Most patients presenting with acute pancreatitis have a mild, self-limiting disease. Rates of patients with idiopathic pancreatitis are high. Recurrent attacks of pancreatitis are common, but are likely to have reduced risk of death on subsequent admissions. </jats:sec

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

    A Non-Realist Non-Starter

    No full text

    Neo-Fregean accounts of the complex numbers and some reflections on Frege's applications constraint

    No full text
    EThOS - Electronic Theses Online ServiceGBUnited Kingdo

    A systematic review to determine the presence and effectiveness of shared decision-making interventions for airway clearance techniques in adults with bronchiectasis

    No full text
    BackgroundBronchiectasis is a chronic lung disorder, impaired muco-ciliary clearance and sputum retention are core elements in bronchiectasis pathophysiology. Airway clearance is regarded as the cornerstone of therapy in bronchiectasis. There is currently a lack of randomised controlled trials (RCTs) proving the efficacy of one specific airway clearance technique (ACT) over another. Shared decision-making (SDM) interventions are usually designed for situations where there is some uncertainty about the best treatment option and provide information about the advantages and disadvantages in as balanced a way as possible.AimsTo determine if and how SDM is used when choosing ACTs for adults with bronchiectasis. To determine the effectiveness of SDM when choosing ACTs for adults with bronchiectasis. Effectiveness will be measured using clinical and patient outcomes including: exacerbation frequency, hospitalisation, adverse events and mortality, patient adherence, health related quality of life, patient preference and acceptance.ObjectivesTo systematically search and identify all studies that include the use of SDM in ACTs in adults with bronchiectasis. To critically appraise and synthesise studies to provide a summary of the effectiveness on the use of SDM in ACTs in adults with bronchiectasis.Search criteriaThe following electronic databases were searched: CINAHL, EMBASE, Medline, PsycINFO, Google Scholar, Web of Science and the Cochrane Library. No limit was set for publication date. The review was limited to English language publications only.ResultsNo studies were identified for inclusion in the review.LimitationsWith no studies meeting criteria for inclusion, it may appear to offer no conclusions or offer conclusions not based on evidence and may seem disappointing among some clinicians and policymakers. We argue that this empty review remains important and highlights a major research gap and has identified the state of the evidence at this point in time in SDM for ACTs in bronchiectasis.ConclusionsBronchiectasis is an increasingly prevalent disease. ACTs are the cornerstone of bronchiectasis management. We have presented clear justification for further research for development of a SDM intervention for ACTs in adults with bronchiectasis

    Suspending employees from work

    No full text
    URN 99/1199Available from British Library Document Supply Centre-DSC:m00/13883 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo

    Rbm24a and Rbm24b Are Required for Normal Somitogenesis

    No full text
    <div><p>We recently demonstrated that the gene encoding the RNA binding motif protein 24 (RBM24) is expressed during mouse cardiogenesis, and determined the developmental requirement for its zebrafish homologs Rbm24a and Rbm24b during cardiac development. We demonstrate here that both Rbm24a and Rbm24b are also required for normal somite and craniofacial development. Diminution of <i>rbm24a</i> or <i>rbm24b</i> gene products by morpholino knockdown resulted in significant disruption of somite formation. Detailed <i>in situ</i> hybridization-based analyses of a spectrum of somitogenesis-associated transcripts revealed reduced expression of the cyclic muscle pattering genes <i>dlc</i> and <i>dld</i> encoding Notch ligands, as well as their respective target genes <i>her7</i>, <i>her1</i>. By contrast expression of the Notch receptors <i>notch1a</i> and <i>notch3</i> appears unchanged. Some RBM-family members have been implicated in pre-mRNA processing. Analysis of affected Notch-pathway mRNAs in <i>rbm24a</i> and <i>rbm24b</i> morpholino-injected embryos revealed aberrant transcript fragments of <i>dlc</i> and <i>dld</i>, but not <i>her1</i> or <i>her7</i>, suggesting the reduction in transcription levels of Notch pathway components may result from aberrant processing of its ligands. These data imply a previously unknown requirement for Rbm24a and Rbm24b in somite and craniofacial development. Although we anticipate the influence of disrupting RBM24 homologs likely extends beyond the Notch pathway, our results suggest their perturbation may directly, or indirectly, compromise post-transcriptional processing, exemplified by imprecise processing of <i>dlc</i> and <i>dld</i>.</p></div
    corecore